Skip to main content
Kalbe Farma Tbk logo

Kalbe Farma Tbk — Investor Relations & Filings

Ticker · KLBF ISIN · US69368A1088 LEI · 529900PRQI8S32HOE387 IDX Manufacturing
Open in API
Filings indexed 13 across all filing types
Latest filing 2026-05-25 Notice of Dividend Amou…
Country ID Indonesia
Listing IDX KLBF

About Kalbe Farma Tbk

https://www.kalbe.co.id/

PT Kalbe Farma Tbk (Kalbe), established in 1966, is a prominent pharmaceutical, healthcare, and nutrition company. It operates across four core divisions: prescription pharmaceuticals, consumer health products, nutritionals, and distribution and logistics. Kalbe's product portfolio encompasses unbranded and branded generic drugs, licensed pharmaceuticals, and medical devices. The company actively engages in vaccine development and provision, exemplified by trivalent influenza vaccines, and supports advancements in nuclear pharmacy through education and collaboration. Leveraging an integrated distribution network, Kalbe serves hospitals, pharmacies, and drug stores, establishing itself as one of Southeast Asia's largest and most integrated pharmaceutical entities, driven by innovation and a commitment to health resilience.

Recent filings

Filing Released Lang Actions
Keterbukaan Informasi terkait Aksi Korporasi - Dividen Tunai - 25052026
Notice of Dividend Amount Classification · 88% confidence The document is an official information disclosure concerning a corporate action – specifically the declaration of a cash dividend for the fiscal year 2025. It provides the total dividend amount, dividend per share, approval by the annual general meeting (RUPS), and detailed schedule of cum/ex‐dividend and payment dates. This matches the “Notice of Dividend Amount” category (DIV).
2026-05-25 Indonesian
Perubahan Pengurus
Board/Management Information Classification · 95% confidence The document is an official announcement from Kalbe Farma Tbk informing shareholders of changes in the company’s board of directors and commissioners, listing new appointments and respective dates. It clearly pertains to Board/Management Information as it details changes in the board composition. There is no financial data, no meeting results, and no reference to a published report—only a management change notice. Therefore, it falls under the Board/Management Information category (MANG).
2026-05-25 Indonesian
Ringkasan Risalah Rapat Umum Para Pemegang Saham Tahunan dan Luar Biasa
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a formal summary of minutes from the Annual and Extraordinary General Meetings of Kalbe Farma Tbk, detailing quorum, vote counts and percentages for each agenda item, and the resulting decisions (e.g., approval of annual report, dividend resolution, board changes, auditor appointment, articles amendment). It is not a financial report itself but a declaration of shareholder vote outcomes. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-05-25 Indonesian
Laporan Bulanan Registrasi Pemegang Efek
Regulatory Filings Classification · 75% confidence The document is a “Monthly Report of Securities Holders Registration” (Laporan Bulanan Registrasi Pemegang Efek) filed by Kalbe Farma Tbk with the stock exchange. It contains detailed tables of share ownership by directors, commissioners, 5% shareholders, free-float calculations, and investor classifications. This is a regulatory compliance filing rather than a financial report (10-K, IR, ER) or a specialized announcement (dividend, M&A, or share issue). It does not present quarterly/interim financial statements or earnings, nor is it simply an announcement of publication. It is therefore best classified as a general regulatory filing.
2026-05-11 Indonesian
KLBF - FY 2020 - FinancialStatement-2020-Tahunan-KLBF.pdf
Annual Report Classification · 95% confidence The document is titled 'Penyampaian Laporan Keuangan Tahunan' which translates to 'Submission of Annual Financial Report'. It contains detailed financial statements including statement of financial position, profit or loss, and other comprehensive income for the year ended 31 December 2020. The document includes auditor information, audit opinion (unqualified), and compliance with regulatory requirements. The length is substantial (15,000 characters) and contains actual financial data and analysis, not just an announcement or certification. Therefore, this is the full Annual Report containing the company's yearly financial performance and activity. FY 2020
2020-12-31 Indonesian
KLBF - FY 2020 - Penjelasan Perubahan Liabilitas KLBF.pdf
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the Indonesian Financial Services Authority and the Indonesia Stock Exchange, explaining a change of more than 20% in total assets and/or total liabilities compared to the last audited annual financial statements. It references the audited consolidated financial statements as of December 31, 2020, and explains the reasons for the increase in liabilities and management's opinion on the impact. The document is relatively short (2511 characters) and serves as a written explanation accompanying the financial report submission, fulfilling a regulatory disclosure requirement. It does not contain the full financial statements or detailed financial data itself, but rather a management explanation of a significant change in financial figures. This fits best with the category of Regulatory Filings (RNS), as it is a compliance disclosure letter rather than a full financial report or audit report.
2020-12-31 Indonesian

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.